NCT01485809View on ClinicalTrials.gov

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

November 30, 2016

Conditions
Squamous Cell Carcinoma of Bronchus
Interventions
DRUG

Gefitinib

Gefitinib 250mg/day, oral daily q every 4 weeks

Trial Locations (1)

134-791

Seoul Veterans Hospital, Seoul

All Listed Sponsors
lead

Seoul Veterans Hospital

OTHER

NCT01485809 - Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy | Biotech Hunter | Biotech Hunter